Stifel Nicolaus Keeps Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)
Medexus Pharmaceuticals Inc Raised to Outperform From Market Perform by Raymond James
Medexus Pharmaceuticals Inc. Initiated at Speculative Buy by Leede Financial
Medexus Pharmaceuticals Inc. Price Target Raised to C$3.50/Share From C$3.00 by Stifel Nicolaus
Stifel Nicolaus Remains a Buy on Medexus Pharmaceuticals Inc (MDP)
Buy Rating for Medexus Pharmaceuticals Inc: Growth Potential on FDA Approval and Strategic Initiatives
Stifel Nicolaus Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)
Medexus Pharmaceuticals Inc Price Target Raised to C$2.80/Share From C$2.35 by Stifel Nicolaus
Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85
Medexus Pharmaceuticals Inc (MDP) Receives a Buy From Bloom Burton
Stifel Nicolaus Sticks to Its Buy Rating for Medexus Pharmaceuticals Inc (MDP)
Echelon Wealth Partners Sticks to Their Buy Rating for Medexus Pharmaceuticals Inc (MDP)
Medexus Pharmaceuticals Inc (MDP) Receives a Buy From Stifel Nicolaus
Medexus Pharmaceuticals Inc (MDP) Gets a Buy Rating From Echelon Wealth Partners
Medexus Pharmaceuticals Inc (MDP) Gets a Buy Rating From Echelon Wealth Partners
Medexus Pharmaceuticals Inc (MDP) Receives a Buy From Echelon Wealth Partners